

1 **COVID-19 Related Chemosensory Changes in Individuals with Self-Reported Obesity**

2

3 **Authors:** Bhutani, S., Coppin, G., Veldhuizen, MG., Parma, V., Joseph, PV

4 **Author Affiliations:**

5 Surabhi Bhutani, School of Exercise and Nutritional Sciences, San Diego State University, San
6 Diego, CA

7 Géraldine Coppin, Department of Psychology, Formation Universitaire à Distance

8 (UniDistance), Brig, Switzerland; Swiss Center for Affective Sciences, University of Geneva,

9 Geneva, Switzerland; geraldine.coppin@unige.ch

10 Maria Geraldine Veldhuizen, Department of Anatomy, Faculty of Medicine, Mersin University,
11 Mersin, Turkey; margaveldhuizen@gmail.com

12 Valentina Parma, Department of Psychology, Temple University; Monell Chemical Senses
13 Center; valentina.parma@temple.edu

14 Paule Valery Joseph, National Institutes of Alcohol Abuse and Alcoholism and National Institute
15 of Nursing Research paule.joseph@nih.gov

16

17 **Contact Information:**

18 Surabhi Bhutani, PhD

19 School of Exercise and Nutritional Sciences

20 San Diego State University

21 ENS Building, room 302

22 5500 Campanile drive

23 San Diego, CA 92182

24 Phone: 619-594-4094

25 sbhutani@sdsu.edu

26

27 **Running Title:** COVID-19 chemosensory decline in obesity

28 **Word Count:** 4000

29 **Funding:** Deployment of the GCCR survey was supported by an unrestricted gift from James
30 and Helen Zallie to support sensory science research at Penn State. Paule V. Joseph is supported
31 by the National Institute of Alcohol Abuse and Alcoholism and the National Institute of Nursing
32 Research. PVJ is also supported by the Office of Workforce Diversity, National Institutes of
33 Health, and the Rockefeller University Heilbrunn Nurse Scholar Award. Maria G. Veldhuizen is
34 supported by the 2232 International Fellowship for Outstanding Researchers Program of
35 TÜBİTAK under award number 118C299.

36 **Disclosures:**

37 **Competing interests:** The authors declare no competing financial interests in relation to the
38 work described.

39

40 **Author Contributions:**

41 All authors conceived the project idea. MG and VP analyzed the data. SB, GC, PJ drafted the
42 manuscript. All authors were involved in editing the paper and had final approval of the
43 submitted and published versions.

44

45

46

47 **Abstract**

48 **Background/objectives:** Individuals with obesity show alterations in smell and taste abilities.

49 Smell and taste loss are also the most prominent neurological symptoms of COVID-19, yet how
50 chemosensory ability present in individuals with obesity with a positive COVID-19 diagnosis is
51 unknown.

52 **Subjects/Methods:** In this secondary analysis of a cross-sectional global dataset, we compared
53 self-reported chemosensory ability in participants with a respiratory illness reporting a positive
54 (C19+; n = 5156) or a negative (C19-; n = 659) COVID-19 laboratory test outcome, who also
55 self-reported to be obese (C19+; n = 433, C19-; n = 86) or non-obese.

56 **Results:** Compared to the C19- group, C19+ exhibited a greater decline in smell, taste, and
57 chemesthesis during illness, though these symptoms did not differ between participants with
58 obesity and without obesity. In 68% of participants who reported recovery from respiratory
59 illness symptoms (n=3431 C19+ and n= 539 C19-), post-recovery chemosensory perception did
60 not differ in C19+ and C19- diagnosis, and by self-reported obesity. Finally, we found that all
61 chemosensory and other symptoms combined predicted the C19+ diagnosis in participants with
62 obesity with a moderately good estimate (63% accuracy). However, in C19+ participants with
63 obesity, we observed a greater relative prevalence of non-chemosensory symptoms, including
64 respiratory as respiratory and GI symptoms.

65 **Conclusions:** We conclude that despite a presumed lower sensitivity to chemosensory stimuli,
66 COVID-19 respondents with obesity experience a similar self-reported chemosensory loss as
67 those without obesity, and in both groups self-reported chemosensory symptoms are similarly
68 predictive of COVID-19.

69 **Keywords:** COVID-19; Smell; Taste; Chemesthesis; Obesity

70 INTRODUCTION

71 According to the World Health Organization, globally 13% of adults aged 18 years and
72 over reported to have obesity in 2016 (1). Within the context of the ongoing COVID-19
73 pandemic, intriguingly, countries with the highest prevalence of obesity also recorded a high
74 death rate from COVID-19 infection (2). Although, an increased in susceptibility to viral
75 infection with obesity is unknown, a recent review by Stefan et al. concluded that obesity is a
76 strong and independent determinant of morbidity and mortality in patients infected with SARS-
77 CoV-2, the virus responsible for COVID-19 infection (3). A recent analysis also indicated that
78 COVID-19 mortality in patients with obesity is higher than that of other comorbidities, including
79 diabetes, hypertension, asthma, and cancer (4). In addition to greater risk for COVID-19 related
80 poor health outcomes (3,5,6), patients with obesity are more likely to require hospitalization,
81 especially in young adults with a Body Mass Index (BMI) >30 kg/m (7). Overall, current
82 evidence suggests that obesity significantly interacts with the pathogenesis of COVID-19.
83 Despite this risk, COVID-19 chemosensory symptoms have not yet been systematically assessed
84 in this population group.

85 Disturbances in smell and taste emerged as a predominant neurological symptom of
86 COVID-19 infection, with 77 percent of COVID-19 patients reporting sudden olfactory and
87 gustatory dysfunctions in a recent meta-analysis (8). In a recent analysis, we also reported
88 quantified smell loss as the best predictor of COVID-19, compared to other common non-
89 chemosensory symptoms (9). However, these studies did not delineate COVID-19-related
90 chemosensory impact in patients with obesity. This is especially important because individuals
91 with obesity typically have existing lower taste sensitivity, and lower capacity to detect and
92 identify odors than individuals without obesity (10). Particularly, excessive body weight has

93 been shown to be associated with impaired taste for sweet and salty foods, alteration in fat/fatty
94 acid-sensing, reduced ability to identify correct taste (11–13) in taste detection thresholds (11–
95 15). These obesity-related chemosensory dysfunctions are driven by production of pro-
96 inflammatory factors from adipose tissues, leading to impairment in olfactory receptors (16) and
97 a decline in taste bud and taste progenitor cells (17,18), respectively. Considering that marked
98 inflammation with obesity also seems to favor viral infections (19,20), the interaction between
99 existing chemosensory deficiency in adults with obesity and COVID-19 related chemosensory
100 impairments are unknown.

101 Existing gustatory and olfactory sensory deficiency due to obesity may mask the viral-
102 induced diminished taste and smell self-reported experiences, leading to a higher portion of
103 undetected cases in this population (21), we need a better understanding of how chemosensory
104 profile changes in patients with obesity. Furthermore, in light of the potential for using oro-naso
105 sensory perception as an early marker of SARS-CoV-2 infection (22–24), it needs to be assessed
106 whether the predictive relation between the chemosensory loss and COVID-19 illness
107 generalizes to participants with obesity. With continually increasing death rates projected well
108 into 2021 using a second statistical model (25), and a wave of infections sweeping through
109 countries worldwide, it is imperative to understand the impact of SARS-COV-2 virus on
110 chemosensory dysfunction in COVID-19 patients in the high-risk category such as populations
111 with excessive body weight. Here, we systematically describe and compare the chemosensory
112 perception (smell, taste, and chemesthesis) and related symptomatology in COVID-19 in non-
113 hospitalized adults with or without self-reported obesity. Following our pre-registered analysis
114 plan (26), we hypothesized that the participants with obesity will report less smell loss during

115 COVID-19 illness. We also hypothesize that smell loss will be less predictive of COVID-19
116 diagnosis than the participants without obesity.

117

118 **METHODS**

119 **Study Design**

120 To the best of our knowledge, this study is the first to assess chemosensory alterations in
121 adults with obesity and COVID-19. We conducted a secondary analysis of cross-sectional
122 survey data collected between April 7th and November 4th, 2020 using the Global Consortium
123 for Chemosensory Research (GCCR) core questionnaire. This crowdsourced survey collected
124 data from community-dwelling individuals via social and traditional media as well as the GCCR
125 website. It was also presented to clinicians to relay to their patients. This survey, currently
126 deployed in 32 languages, used binary-response and categorical questions, as well as visual
127 analog scales to measure self-reported chemosensory ability and other symptoms in adults with
128 ongoing or recent respiratory illnesses (22). We also collected self-reported data on the presence
129 of pre-existing diseases, including our condition of interest, obesity, as well as other COVID-19
130 symptoms All participants included in the study were: 1) ≥ 18 years old, 2) had a (suspected)
131 respiratory illness within the past two weeks, 3) had onset of respiratory illness after January 1,
132 2020, 4) reported COVID-19 diagnosis via laboratory test (viral PCR or antigen test).
133 Respondents who did not report having any illness or symptoms within the last two weeks, who
134 had multiple responses, or who responded “Don’t know” or “Other” when asked about their
135 diagnosis of COVID-19, were excluded from the analyses. To investigate the recovery of
136 chemosensory functions, only participants who reported the date of onset of respiratory illness
137 symptoms were included. The original study was approved by the Office of Research Protections

138 of The Pennsylvania State University (STUDY00014904). The hypotheses and analyses in this
139 manuscript were pre-registered at <https://osf.io/xf25v> (26) and the research compendium
140 including data files and analysis scripts is available at <https://osf.io/rbcty/>. Specifically, our
141 analyses aimed to describe chemosensory perception and related symptomatology during the
142 COVID-19 illness (Aim 1) and post-vs pre-COVID-19 diagnosis (Aim 2), in participants with
143 self-reported obesity vs without obesity. We predicted lower ratings for smell, taste, and
144 chemesthesis, and more severe COVID-19 symptoms in participants with obesity, compared to
145 without obesity. We also speculated smaller differences in ratings for smell, taste, and
146 chemesthesis perception post- vs pre- COVID diagnosis in participants with self-reported
147 obesity. Post-COVID-19 chemosensory recovery (Aim 3) was also tested, hypothesizing that
148 participants will have lower ratings for smell, taste, and chemesthesis post-COVID-19 recovery
149 in participants with self-reported obesity vs without obesity. Additionally, we assessed COVID-
150 19 severity as measured based on the sum of reported symptoms (Aim 4), and the ability of smell
151 ratings to predict COVID-19 diagnosis (Aim 5), in participants with self-reported obesity vs
152 without obesity.

153 A departure from the pre-registered analyses is the inclusion of age as a factor in all
154 analyses, following differences in age we observed between groups. We also report the
155 unregistered analysis of pre-illness ratings, an important addition given the previously reported
156 decreased sensitivity for participants with obesity compared to those without obesity.

157

158 **Participant Description**

159 A convenience sample of 52334 volunteers accessed the GCCR questionnaire. Of those
160 individuals, 5815 met the inclusion and exclusion eligibility criteria and were included in the

161 final analysis. A positive COVID-19 diagnosis (C19+) was determined using the self-reported
162 data from COVID-19 lab test or clinical exam outcome. All C19+ patients were further
163 categorized into having obesity if they reported it as one of the pre-existing disease conditions in
164 the questionnaire. C19+ patients who did not report having any medical condition or did not
165 answer this question on pre-existing disease conditions were categorized as controls without
166 obesity. We also included a control group of participants without obesity. See Figure 1. for a
167 flow diagram of the inclusion of participants into the various groups.

168

169 **Statistical Analyses**

170 Statistical analyses were conducted in R (27) via RStudio. The annotated scripts, the
171 information on the computational environment, and dependencies shared for future
172 reproducibility will be found, upon acceptance of the manuscript, at the OSF project link, which
173 includes directions to the GitHub page at which the code is stored.
174 No negative value appeared in the survey responses. Whenever in question 38 (prior conditions),
175 no response was provided or the option “None” was checked, the response was imputed as
176 indicating no prior conditions. Prediction targets were never imputed. All open-ended questions
177 were excluded as they are incompatible with model generalization.

178

179 *Demographics*

180 Cognizant of possible null effects in all our analyses, we opted to implement a Bayesian
181 approach, which allows us to estimate the strength of the evidence supporting the null
182 hypothesis. To test via a between-participant sequential Bayes factor design whether a difference
183 between groups was present (H1) or absent (H0), we conducted Bayesian linear regressions with

184 the lmBF function from the BayesFactor package (28). We used the default Cauchy prior on the
185 effect sizes under the H1 as the scale parameter spread, which was set at its default value of $r =$
186 $\sqrt{2}/2$. To test for a difference in age between groups, we used the following full model: Age
187 \sim COVID diagnosis + Obesity Age + COVID diagnosis x Obesity. Additive models (no
188 interaction) and main effect models were also computed and compared to determine the model
189 that best explained the data pattern, aka the model comparison with the most extreme Bayes
190 Factor. Please refer to **Supplementary Table 1** for the inference rules, which follows the
191 classification scheme proposed by Lee and Wagenmakers (29) and adjusted from (30). To
192 interpret the strength and the direction of the effects identified, we have additionally sampled
193 from the models' posterior distributions (iterations = 1e4). To test for gender differences between
194 groups, we calculated probability tables of women and men in each of the COVID-19 and
195 obesity groups and tested for distribution differences with Pearson's chi-square tests with the R
196 base function "prop.test". We used an alpha of 0.05 to determine significance.

197

198 *Self-reported Chemosensory perception analyses*

199 For chemosensory perception analyses, we also conducted Bayesian linear regressions
200 with the lmBF function. The full model included the following terms: Dependent variable \sim
201 COVID diagnosis + Obesity Age + COVID diagnosis x Obesity. Additive models (no
202 interaction) and main effect models were also computed and compared to determine the model
203 that best explained the data pattern. Age was included in all models to factor in significant
204 associations between age and obesity. We used "before illness", "during illness", "change due to
205 illness" ("before illness" minus "during illness") and "recovery" ("after illness" minus "during
206 illness") separately as dependent variables.

207

208 *Other illness symptomatology analyses*

209 To assess whether participants with obesity experience more and/or different symptoms
210 from those without obesity, we summed all symptoms that participants reported (each symptom
211 that was reported was assigned a value of 1). We then conducted Bayesian linear regressions
212 with the lmBF function as above with summed symptoms as the dependent variable (as above in
213 the chemosensory analyses). We operationalized disease duration as the number of days since
214 onset of the illness and used “days since onset” as the dependent variable in Bayesian linear
215 regression (models as above). For the subset of COVID-19 patients only, we calculated
216 probability tables for the likelihood of experiencing a given symptom for the participants with
217 and without obesity and tested for distribution differences with chi-square tests (details as above
218 under demographics). We used an alpha of 0.05 to determine significance.

219

220 *Model accuracy for predicting COVID-19 illness*

221 To deal with binary classification problems in the presence of imbalanced classes, we
222 used the ROSE (Random Over-Sampling Examples) package (31), which generates synthetic
223 balanced samples and thus allows to strengthen the subsequent estimation of any binary
224 classifier. To measure model quality, receiver operating characteristic (ROC) were visualized via
225 the pROC package (32) based on the calculation of hold-out area under the curve (AUC), which
226 summarizes the tradeoff between sensitivity (fraction of correctly identified C19+ cases in the
227 sample with obesity and without obesity) and specificity (fraction of correctly identified C19-
228 cases in the sample with obesity and without obesity) as the threshold value for the predictor is
229 varied. We used symptoms (binary), number of symptoms, chemosensory ratings during illness,

230 COVID diagnosis, and days since onset of the respiratory illness. We focused on “during illness”
231 ratings because those best showed evidence for the effects of illness and were also the most
232 predictive symptom in a previous study with the same questionnaire (9). Moreover, this question
233 (rather than pre-illness ratings or change in ratings) is best suited for being asked when making
234 an inventory of symptoms in a clinical setting.

235

236 **RESULTS**

237 **Participant Characteristics**

238 A total of 5156 participants reported a positive lab test for COVID-19 (hereafter, C19+),
239 while 659 reported a negative lab test for COVID-19 (hereafter, C19-). Of all participants, 519
240 (9% of the total group) self-reported to have obesity (C19+ = 433; C19- = 86) (**Figure 1**). The
241 demographic profile of our participants is summarized in **Supplementary Table 2 a and b**. Age
242 is higher in OB+ compared to OB- (43.1 vs 39.5) ($BF_{10} = 7.48e+06 \pm 0\%$). After excluding $n =$
243 17 participants with gender reporting categories of “prefer not to say” ($n = 13$) and “other” ($n =$
244 4), we observed different proportions of gender ($\chi^2 = 4.42$, $p = 0.035$), driven primarily by a
245 higher proportion of women in the C19- group with obesity (87.2%) compared to those without
246 obesity (77%).

247

248 **Before COVID-19 illness, participants with obesity exhibit similar smell, taste, and** 249 **chemesthesis loss as those without obesity before COVID-19 illness**

250 Before COVID-19 illness, OB+ participants did not self-report greater ability in smell
251 (change against zero, $BF_{10} = 6.48e-02 \pm 0\%$), taste ($BF_{10} = 7.24e-02 \pm 0\%$) or chemesthesis
252 ($BF_{10} = 7.89e-02 \pm 0\%$), or greater nasal congestion ($BF_{10} = 6.80e-02 \pm 0\%$) than OB-

253 participants (**Supplementary Figure 1, Supplementary Table 3**). Before COVID-19 illness
254 C19+ participants reported greater ability in smell ($BF_{10} = 2.16e+01$) and taste ($BF_{10} = 3.45e+02$
255 $\pm 0\%$) than C19- participants.

256

257 **During COVID-19 illness, participants with obesity exhibit similar smell, taste, and**
258 **chemesthesis loss as those without obesity during COVID-19 illness**

259 C19+ participants reported greater deficits in smell (change against zero: $BF_{10} =$
260 $1.20e+75 \pm 0\%$), taste (change against zero: $BF_{10} = 1.51e+29 \pm 0\%$), and chemesthesis (change
261 against zero: $BF_{10} = 1.69e+05 \pm 0\%$), as compared with C19- participants (**Figure 2,**
262 **Supplementary Table 4**). Similar to our previous report (22), we reported lower deficits in nasal
263 congestion with C19+ participants in our analysis (change against zero: $BF_{10} = 1.56e+01 \pm 0\%$),
264 compared to C19- participants. Further, these chemosensory variables did not differ between the
265 participants who self-reported obesity vs participants without obesity (smell $BF_{10} = 1.44e-01 \pm$
266 0% ; taste $5.7e-02 \pm 0\%$; chemesthesis $8.22e-01 \pm 0\%$), across the COVID groups.

267 Similar to the above chemosensory findings during the illness, the differences in chemosensory
268 ratings between pre-and during illness varied in C19+ and C19- participants (**Figure 3,**

269 **Supplementary Table 5**). In particular, C19+ participants reported greater deficits in smell
270 (change against zero: $BF_{10} = 5.18e+59 \pm 0\%$), taste (change against zero: $BF_{10} = 1.46e+32 \pm 0\%$),
271 and chemesthesis (change against zero: $BF_{10} = 6.82e+07 \pm 0\%$), than the C19- group. However,
272 when estimating the effect of obesity condition, the three chemosensory variables did not differ
273 between the groups with obesity and without obesity across the COVID-19 condition (smell
274 change against zero; $BF_{10} = 6.71e-02 \pm 0\%$; taste change against zero $BF_{10} = 5.28e-02 \pm 0\%$;

275 chemesthesis change against zero $BF_{10} = 1.26e-01 \pm 0\%$). Interestingly, there was no main effect
276 of COVID-19 condition or obesity status on the nasal obstruction reporting.

277

278 **Participants with obesity exhibit similar smell, taste, and chemesthesis recovery from**
279 **COVID-19 illness as those without obesity**

280 To further understand changes in chemosensory perception with COVID-19 diagnosis
281 and obesity condition, we looked at the data from participants who reported recovery from the
282 illness (**Figure 4, Supplementary Table 6**). Recovery was reported by 3970 participants
283 ($n=3431$ C19+ and $n= 539$ C19-), which is approximately 68% of our sample. Our Bayesian
284 linear models suggest that the ratings for post-recovery chemosensory perception (smell $BF_{10} =$
285 $7.79e-02 \pm 0.02\%$; taste $BF_{10} = 6.44e-02 \pm 0.02\%$; chemesthesis $BF_{10} = 2.18e-01 \pm 0.01\%$) did
286 not differ in C19+ and C19- diagnosis. Of note, some smell/taste/chemosensory symptoms
287 remain post-recovery from the illness in C19+ and C19- groups. We found no differences in
288 smell ($BF_{10} = 6.58e-02 \pm 0.02\%$), taste ($BF_{10} = 1.07e-01 \pm 0.02\%$), and chemesthetic perception
289 ($BF_{10} = 9.96e-02 \pm 0.11\%$) by self-reported obesity. Nasal obstruction did not seem to be
290 affected by either COVID-19 diagnosis ($BF_{10} = 5.33e-02 \pm 0.03\%$) or obesity status (BF_{10}
291 $=8.16e-02 \pm 0.02\%$) post-recovery from the illness.

292

293 **Participants with obesity report more symptoms overall and more frequently report**
294 **respiratory and gastrointestinal (GI) symptoms.**

295 Based on the evidence from existing clinical and epidemiological studies, one of our
296 goals was to assess whether individuals with self-reported obesity overall have greater
297 symptomatic manifestation with C19+ diagnosis than those participants without obesity. To test

298 our hypothesis, we used Bayesian linear regression and compared the sum of the symptoms
299 reported by participants in these samples versus samples without obesity (**Figure 5A,**
300 **Supplementary Table 8**). As predicted, among those with C19+, there is decisive evidence that
301 participants with obesity report a larger number of symptoms than participants without obesity
302 ($BF_{10} = 1.02e04 \pm 0\%$; average N of symptoms = with obesity: 8.22; without obesity: 7.42). A
303 similar effect is observed among participants with C19- (average N of symptoms = with obesity:
304 8; without obesity: 7.33 $BF_{10} = 9.91e03 \pm 0\%$). Among those with C19+, disease duration is
305 longer in those with obesity ($BF_{10} = 1.02e04 \pm 0\%$; average days since onset), while in C19- such
306 a difference is not observed ($BF_{10} = 1.21e00 \pm 0\%$ (**Figure 5B, Supplementary Table 7**)).
307 Looking at the specific symptoms (**Figure 5C**), smell and taste symptoms are equally reported
308 by participants with obesity and participants without obesity with a diagnosis of COVID-19.
309 Further, participants with self-reported obesity reported greater frequency in loss of appetite,
310 diarrhea, and nausea, along with shortness of breath, cough (dry or with mucus), and chest
311 tightness.

312

313 **A classifier trained on participants without obesity accurately predicts C19+ diagnosis in** 314 **participants with obesity**

315 Based on the self-reports on symptoms, combined with the chemosensory and nasal
316 obstruction ratings, we assessed the accuracy with which we could predict a C19+ diagnosis
317 (**Figure 6**) in OB-. We then tested the model to predict the accuracy of discrimination of C19+ in
318 participants with obesity. Our results indicate that we can predict the C19+ diagnosis with 63%
319 accuracy, which indicates a moderately good estimate. Variables included in this analysis are
320 reported in **Supplementary Table 8**.

321

322 **DISCUSSION**

323 Since the beginning of the COVID-19 pandemic, reports of olfactory and gustatory
324 dysfunctions in COVID-19 patients continue to grow. To our knowledge, this study is the first to
325 describe and compare the chemosensory perception and related symptomatology in COVID-19
326 patients who self-reported to have obesity vs. no obesity. Independent of the obesity status, the
327 subjective ratings of smell, taste, and chemesthesis declined with COVID-19 illness. Examining
328 the recovery patterns, we found that participants with obesity show similar recovery from
329 COVID-19 related loss of smell, taste, and chemesthesis as those without obesity. Although we
330 do not know the severity of each symptom, those with obesity reported a greater frequency of
331 respiratory and GI symptoms and more symptoms overall. Finally, we found that a model of all
332 symptoms combined that was trained on patients without obesity is, can predict the C19+
333 diagnosis with 63% of accuracy in participants with obesity. Furthermore, this smell loss was not
334 related to self-reported nasal obstruction, commonly observed in other upper respiratory
335 infections (33,34). Together, these results confirm and add to previous reports that COVID-19
336 largely impacts chemosensory function; however, obesity does not mask self-reported
337 chemosensory loss in those with a COVID diagnosis.

338 Smell and taste disturbances are a typical consequence of nasal inflammation due to an
339 upper respiratory tract viral infection (35,36); however, an acute loss of taste and smell emerged
340 rapidly as a critical neurological manifestation of a positive COVID-19 diagnosis (37). Our
341 current findings are similar to prior reports that showed that approximately 90% of the
342 participants reported a loss of smell. Furthermore, nearly 80% of the participants reported a loss
343 of taste, and 46% had a reduction of chemesthesis (detection of chemicals that induce tingling

344 and burning sensations such as the burning of chili peppers), indicating that the chemosensory
345 impairment is not restricted to smell (9,22). While most cold viruses cause nasal congestion and
346 individuals experience a reduction in the sense of smell, our results showed that nasal congestion
347 was not associated with smell loss. This finding is consistent with other reports (38–40) where
348 individuals with COVID-19 do not report clinically significant nasal congestion or rhinorrhea,
349 suggesting that other mechanisms may play a role in COVID-19 associated smell loss (37).

350 In addition to being a risk factor for COVID-19 viral infection, excessive body weight is
351 also implicated in chemosensory decline. Adipose tissue in obesity is “pro-inflammatory”,
352 causing a surge in levels of IL-6 and C-reactive protein and enhancing the expression of
353 cytokines and adipokines (41). Interestingly, in diseases where these circulating inflammatory
354 factors are high, smell and taste dysfunction are prevalent (42,43). In particular, acute induction
355 of systemic inflammation has been shown to shorten the lifespan of adult taste bud cells (18).
356 Similarly, enhanced expression of inflammatory markers is shown to reduce olfactory sensory
357 neurons, in mice fed a high-fat diet to induce obesity (44). Thus, obesity-related inflammation
358 may affect chemosensory function. A major concern with this pre-existing gustatory and
359 olfactory sensory deficiency due to obesity is that obesity may mask the viral-induced
360 diminished taste and smell self-reported experiences. Interestingly, our analysis showed that
361 COVID-19 related chemosensory-related changes were comparable between C19+ participants
362 with obesity and without obesity suggesting that obesity does not have an effect on the loss of
363 chemosensory perception with COVID diagnosis. These findings need to be taken with caution,
364 especially when considering severe cases, which are more common in patients with obesity. For
365 example, if a patient is in critical condition, they cannot pay attention to their chemosensory

366 alterations, and chemosensory perception will likely not be tested or self-reported. This does not
367 mean that the chemosensory perception is not affected.

368 In terms of chemosensory recovery, we found no differences between participants with
369 obesity compared to those without obesity. While none of the studies to date have compared the
370 recovery rates between C19+ participants with obesity vs no obesity, our overall recovery rate of
371 65% is comparable to our previous analysis (9) but slightly lower than other studies (45,46).
372 There are residuals smell/taste/chemosensory symptoms reported post-recovery from the illness
373 in C19+ and C19- groups. In particular, quantitative studies using psychophysical methods have
374 shown that nearly 25% of people continue to report chemosensory problems when evaluated 30 -
375 60 days after the onset of COVID-19 (45). This insufficient recovery rate may significantly
376 increase the number of patients with chemosensory disturbances, ultimately influencing eating
377 behaviors (47), quality of life (48,49), and psychological health (50,51) in the general population.
378 But most importantly, it may significantly impact participants with obesity who have an added
379 burden of lower chemosensory acuity due to excess fat mass (44,52). Thus, it is imperative to
380 prepare healthcare workers to detect and treat chemosensory disorders in this high-risk
381 population.

382 As we hypothesized, non-chemosensory symptoms were more severe in C19+
383 participants with obesity than in participants without obesity. Specifically, participants with
384 obesity reported a greater frequency of respiratory and GI symptoms. In general, it is known that
385 obesity is associated with GI symptoms disturbances, such as upper abdominal pain, nausea,
386 vomiting, retching, and gastritis. GI symptoms are accompanied by inflammation or alterations
387 of intestinal permeability (53–56). However, it also emerged that COVID-19 patients
388 experienced several GI symptoms such as diarrhea (24.2%), anorexia (17.9%), and nausea

389 (17.9%) (57), though they vary widely and are less understood. However, this may not be
390 surprising since some viral infections are known to cause alterations in intestinal permeability as
391 well (58). The mediation of ACE2 cell receptors could elucidate the mechanism related to GI
392 tract involvement in SARS-CoV-2 infection. While ACE2 is expressed in abundance in the
393 lungs' alveolar cells, the receptor is also highly expressed in the GI tract, especially in the small
394 and large intestines (59–63).

395 Our study has some limitations. Our online survey and sampling methodology likely
396 selected participants with a heightened interest in smell and taste and/or their disturbances. Due
397 to that, the data collected at the peak of the pandemic obesity was self-reported; thus, we
398 acknowledge the potential under-reporting of obesity. We also acknowledge that due to the
399 nature of our data being collected in several countries, the definition of obesity may vary and
400 there may be regional and cultural factors that may influence stigma and biases towards self-
401 report of obesity. Ideally, future studies using quantitative taste and smell measures will be
402 conducted in this population. However, although the taste and smell reports were also self-
403 reports, similar to prior studies, we demonstrate that self-reported taste and smell may be a
404 helpful tool to distinguish between C19+ and C19–.

405 Despite the limitations, our study shows differences in participants with obesity
406 compared to participants without obesity with other symptoms. However, those differences
407 potentially do not affect the chemosensory symptoms. In general, more evidence is needed to
408 understand biological mechanisms related to alterations in taste and smell loss in individuals
409 with COVID-19. Understanding how the alteration initiates and progresses will provide
410 molecular and cellular bases for diagnosis and treatment of chemosensory disorders for those
411 with COVID-19 and others who lose their sense of taste and smell due to other conditions with

412 underlying inflammation. While it is an exciting prospect, the use of chemosensory assessments
413 as an effective tool for screening and treatment protocols, and the possibility of integrating these
414 tests into current COVID-19 screening protocols have yet to be determined in the general
415 population, as well as high-risk populations with obesity.

416

417 **Acknowledgments**

418 The authors wish to thank all study participants, patients, and patient advocates that have
419 contributed to this project.

420

421 **REFERENCES**

- 422 1. Obesity and overweight [Internet]. World Health Organization Fact Sheet Obesity and
423 Overweight. 2021 [cited 2021 Jan 25]. Available from: [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)
424 [room/fact-sheets/detail/obesity-and-overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)
- 425 2. Max Roser EO-O Hannah Ritchie, Hasell J. Coronavirus Pandemic (COVID-19). Our
426 World Data. 2020;
- 427 3. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity,
428 impaired metabolic health and COVID-19. *Nat Rev Endocrinol*. 2021 Jan 21;
- 429 4. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
430 associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020
431 Aug;584(7821):430–6.
- 432 5. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al.
433 Association of Obesity with Disease Severity Among Patients with Coronavirus Disease
434 2019. *Obesity*. 2020;28(7):1200–4.

- 435 6. Zhu X, Yang L, Huang K. COVID-19 and Obesity: Epidemiology, Pathogenesis and
436 Treatment. *Diabetes Metab Syndr Obes Targets Ther.* 2020 Dec 14;13:4953–9.
- 437 7. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in
438 Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. *Clin*
439 *Infect Dis Off Publ Infect Dis Soc Am.* 2020 28;71(15):896–7.
- 440 8. Hannum ME, Ramirez VA, Lipson SJ, Herriman RD, Toskala AK, Lin C, et al. Objective
441 Sensory Testing Methods Reveal a Higher Prevalence of Olfactory Loss in COVID-19–
442 Positive Patients Compared to Subjective Methods: A Systematic Review and Meta-
443 Analysis. *Chem Senses.* 2020 Dec 5;45(9):865–74.
- 444 9. Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakke AJ, et al. Recent smell
445 loss is the best predictor of COVID-19 among individuals with recent respiratory
446 symptoms. *Chem Senses [Internet].* 2020 Dec 25 [cited 2021 Jan 13];(bjaa081). Available
447 from: <https://doi.org/10.1093/chemse/bjaa081>
- 448 10. Uygun B, Kiyici S, Ozmen S, Gul Z, Sigirli D, Cavun S. The Association Between
449 Olfaction and Taste Functions with Serum Ghrelin and Leptin Levels in Obese Women.
450 *Metab Syndr Relat Disord.* 2019 Nov;17(9):452–7.
- 451 11. Tucker RM, Edlinger C, Craig BA, Mattes RD. Associations Between BMI and Fat Taste
452 Sensitivity in Humans. *Chem Senses.* 2014 May 1;39(4):349–57.
- 453 12. Bertoli S, Laureati M, Battezzati A, Bergamaschi V, Cereda E, Spadafranca A, et al. Taste
454 sensitivity, nutritional status and metabolic syndrome: Implication in weight loss dietary
455 interventions. *World J Diabetes.* 2014 Oct 15;5(5):717–23.
- 456 13. Low JYQ, Lacy KE, McBride R, Keast RSJ. The Association between Sweet Taste
457 Function, Anthropometry, and Dietary Intake in Adults. *Nutrients.* 2016 Apr 23;8(4):241.

- 458 14. Fernández-Aranda F, Agüera Z, Fernández-García JC, Garrido-Sanchez L, Alcaide-Torres
459 J, Tinahones FJ, et al. Smell-taste dysfunctions in extreme weight/eating conditions:
460 analysis of hormonal and psychological interactions. *Endocrine*. 2016 Feb;51(2):256–67.
- 461 15. Fernandez-Garcia JC, Alcaide J, Santiago-Fernandez C, Roca-Rodriguez MM, Aguera Z,
462 Baños R, et al. An increase in visceral fat is associated with a decrease in the taste and
463 olfactory capacity. *PloS One*. 2017;12(2):e0171204.
- 464 16. Thiebaud N, Johnson MC, Butler JL, Bell GA, Ferguson KL, Fadool AR, et al.
465 Hyperlipidemic diet causes loss of olfactory sensory neurons, reduces olfactory
466 discrimination, and disrupts odor-reversal learning. *J Neurosci Off J Soc Neurosci*. 2014
467 May 14;34(20):6970–84.
- 468 17. Besnard P, Passilly-Degrace P, Khan NA. Taste of Fat: A Sixth Taste Modality? *Physiol*
469 *Rev*. 2016 Jan;96(1):151–76.
- 470 18. Kaufman A, Choo E, Koh A, Dando R. Inflammation arising from obesity reduces taste bud
471 abundance and inhibits renewal. *PLOS Biol*. 2018 Mar 20;16(3):e2001959.
- 472 19. Huttunen R, Syrjänen J. Obesity and the outcome of infection. *Lancet Infect Dis*. 2010
473 Jul;10(7):442–3.
- 474 20. Nave H, Beutel G, Kielstein JT. Obesity-related immunodeficiency in patients with
475 pandemic influenza H1N1. *Lancet Infect Dis*. 2011 Jan;11(1):14–5.
- 476 21. Khan AS, Hichami A, Khan NA. Obesity and COVID-19: Oro-Naso-Sensory Perception. *J*
477 *Clin Med*. 2020 Jul;9(7):2158.
- 478 22. Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More Than
479 Smell—COVID-19 Is Associated With Severe Impairment of Smell, Taste, and
480 Chemesthesis. *Chem Senses*. 2020 Oct 9;45(7):609–22.

- 481 23. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time
482 tracking of self-reported symptoms to predict potential COVID-19. *Nat Med.*
483 2020;26:1037–40.
- 484 24. Foster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M. Smell loss is a prognostic
485 factor for lower severity of coronavirus disease 2019. *Ann Allergy Asthma Immunol.* 2020
486 Oct 1;125(4):481–3.
- 487 25. Reiner RC, Barber RM, Collins JK, Zheng P, Adolph C, Albright J, et al. Modeling
488 COVID-19 scenarios for the United States. *Nat Med.* 2020 Oct 23;1–12.
- 489 26. Bhutani S, Parma V, Joseph PV, Coppin G, Veldhuizen M. Chemosensory dysfunction as a
490 reliable marker for COVID-19 in adults with self-reported obesity [Internet]. 2020.
491 Available from: osf.io/xf25v
- 492 27. Team R Core Development. R: The R Project for Statistical Computing [Internet]. 2013
493 [cited 2021 Feb 9]. Available from: <https://www.r-project.org/>
- 494 28. Morey RD, Rouder JN, Jamil T, Urbanek S, Forner K, Ly A. BayesFactor: Computation of
495 Bayes Factors for Common Designs [Internet]. 2018 [cited 2021 Feb 9]. Available from:
496 <https://CRAN.R-project.org/package=BayesFactor>
- 497 29. Lee MD, Wagenmakers E-J. Bayesian Cognitive Modeling: A Practical Course [Internet].
498 Cambridge: Cambridge University Press; 2013 [cited 2020 Jul 19]. Available from:
499 <http://ebooks.cambridge.org/ref/id/CBO9781139087759>
- 500 30. Jeffreys H. *The Theory of Probability*. OUP Oxford; 1998. 474 p.
- 501 31. Lunardon N, Menardi G, Torelli N. ROSE: a Package for Binary Imbalanced Learning. *R J.*
502 2014;6(1):79.
- 503 32. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-

- 504 source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics*.
505 2011 Mar 17;12(1):77.
- 506 33. Akerlund A, Bende M, Murphy C. Olfactory threshold and nasal mucosal changes in
507 experimentally induced common cold. *Acta Otolaryngol (Stockh)*. 1995 Jan;115(1):88–92.
- 508 34. Doty RL, Mishra A. Olfaction and Its Alteration by Nasal Obstruction, Rhinitis, and
509 Rhinosinusitis. *The Laryngoscope*. 2001;111(3):409–23.
- 510 35. Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral-associated olfactory loss
511 in the era of COVID-19. *Int Forum Allergy Rhinol*. 2020;10(7):814–20.
- 512 36. Hummel T, Landis BN, Hüttenbrink K-B. Smell and taste disorders. *GMS Curr Top*
513 *Otorhinolaryngol Head Neck Surg*. 2011;10:Doc04.
- 514 37. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al.
515 COVID-19 and the chemical senses: supporting players take center stage. *Neuron*
516 [Internet]. 2020 Jul [cited 2020 Jul 2]; Available from:
517 <https://linkinghub.elsevier.com/retrieve/pii/S0896627320304864>
- 518 38. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of
519 Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China [Internet]. *JAMA*
520 *Neurology*. 2020. Available from:
521 <https://jamanetwork.com/journals/jamaneurology/fullarticle/2764549>
- 522 39. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of
523 Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study.
524 *medRxiv*. 2020;2020.02.22.20026500.
- 525 40. Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least
526 partially responsible for the respiratory failure of COVID-19 patients [Internet]. *Journal of*

- 527 Medical Virology. 2020. Available from:
528 <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25728>
- 529 41. Heredia FP de, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune
530 system. *Proc Nutr Soc.* 2012 May;71(2):332–8.
- 531 42. Rawson NE, Huang L. Symposium Overview. *Ann N Y Acad Sci.* 2009;1170(1):581–4.
- 532 43. Wang H, Zhou M, Brand J, Huang L. Inflammation and Taste Disorders. Vol. 1170, *Annals*
533 *of the New York Academy of Sciences.* 2009. p. 596–603.
- 534 44. Riera CE, Tsaousidou E, Halloran J, Follett P, Hahn O, Pereira MMA, et al. The Sense of
535 Smell Impacts Metabolic Health and Obesity. *Cell Metab.* 2017 Jul 5;26(1):198-211.e5.
- 536 45. Niklassen AS, Draf J, Huart C, Hintschich C, Bocksberger S, Trecca EMC, et al. COVID-
537 19: Recovery from Chemosensory Dysfunction. A Multicentre study on Smell and Taste.
538 *The Laryngoscope.* 2021 Jan 6;
- 539 46. Reiter ER, Coelho DH, Kons ZA, Costanzo RM. Subjective smell and taste changes during
540 the COVID-19 pandemic: Short term recovery. *Am J Otolaryngol.* 2020 Dec;41(6):102639.
- 541 47. Kershaw JC, Mattes RD. Nutrition and taste and smell dysfunction. *World J*
542 *Otorhinolaryngol - Head Neck Surg.* 2018 Mar 1;4(1):3–10.
- 543 48. Smeets MAM, Veldhuizen MG, Galle S, Gouweloos J, de Haan A-MJA, Vernooij J, et al.
544 Sense of smell disorder and health-related quality of life. *Rehabil Psychol.* 2009
545 Nov;54(4):404–12.
- 546 49. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review.
547 *Chem Senses.* 2014 Mar;39(3):185–94.
- 548 50. Malaty J, Malaty IAC. Smell and taste disorders in primary care. *Am Fam Physician.* 2013
549 Dec 15;88(12):852–9.

- 550 51. Croy I, Symmank A, Schellong J, Hummel C, Gerber J, Joraschky P, et al. Olfaction as a
551 marker for depression in humans. *J Affect Disord.* 2014 May 1;160:80–6.
- 552 52. Peng M, Coutts D, Wang T, Cakmak YO. Systematic review of olfactory shifts related to
553 obesity. *Obes Rev.* 2019;20(2):325–38.
- 554 53. Nam SY. Obesity-Related Digestive Diseases and Their Pathophysiology. *Gut Liver.* 2017
555 May 15;11(3):323–34.
- 556 54. Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity.
557 *Gastroenterology.* 2017 May 1;152(7):1656–70.
- 558 55. Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-Linked Gut
559 Microbiome Dysbiosis Associated with Derangements in Gut Permeability and Intestinal
560 Cellular Homeostasis Independent of Diet. Fiorina P, editor. *J Diabetes Res.* 2018 Sep
561 3;2018:3462092.
- 562 56. Moss O, Keshavarzian A, Tangney C, Shawron K, Kester K, Shaikh M, et al. Headache, GI
563 symptoms and Intestinal Permeability in Obese Adults. *FASEB J.* 2016;30(S1):1166.7-
564 1166.7.
- 565 57. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95
566 cases with SARS-CoV-2 infection. *Gut.* 2020 Jun 1;69(6):997–1001.
- 567 58. Labarta-Bajo L, Nilsen SP, Humphrey G, Schwartz T, Sanders K, Swafford A, et al. Type I
568 IFNs and CD8 T cells increase intestinal barrier permeability after chronic viral infection. *J*
569 *Exp Med [Internet].* 2020 Sep 3 [cited 2021 Feb 19];217(e20192276). Available from:
570 <https://doi.org/10.1084/jem.20192276>
- 571 59. Jin X, Lian J-S, Hu J-H, Gao J, Zheng L, Zhang Y-M, et al. Epidemiological, clinical and
572 virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19)

- 573 with gastrointestinal symptoms. *Gut*. 2020 Jun;69(6):1002–9.
- 574 60. Parasa S, Desai M, Thoguluva Chandrasekar V, Patel HK, Kennedy KF, Roesch T, et al.
575 Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With
576 Coronavirus Disease 2019: A Systematic Review and Meta-analysis. *JAMA Netw Open*.
577 2020 Jun 11;3(6):e2011335–e2011335.
- 578 61. Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut
579 microbiome. *Transl Res*. 2020 Dec 1;226:57–69.
- 580 62. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, Goor H van. Tissue distribution
581 of ACE2 protein, the functional receptor for SARS coronavirus. A first step in
582 understanding SARS pathogenesis. *J Pathol*. 2004;203(2):631–7.
- 583 63. Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene
584 ACE2 in a wide variety of human tissues. *Infect Dis Poverty*. 2020 Apr 28;9(1):45.

585

586

587 **FIGURE LEGENDS**

588

589 **Figure 1.** Flow Diagram of Study Participants Based on the STrengthening the Reporting of
590 OBservational Studies in Epidemiology (STROBE) guidelines. Participants included in the
591 prediction of COVID-19 status in participants with obesity vs without obesity are framed in blue.
592 Participants framed in purple are included in all other analyses. n = number of participants; OB+
593 = self-reported presence of obesity; OB- = self-reported presence of obesity; COVID diagnosis
594 unclear = responses “No - I do not have any symptoms”, “Don’t know” or “Other” to survey
595 Question 8 (“Have you been diagnosed with COVID-19?”).

596

597

598 **Figure 2.** Self-reported smell (A), taste (B), chemesthesis (C), and nasal obstruction (D) ratings
599 during the illness in C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or
600 without obesity (OB-). Ratings were given on 0-100 visual analog scales. Nasal obstruction
601 question was formulated as “How blocked was your nose?”) during respiratory illness in C19+
602 and C19- participants. Each panel presents the mean ratings for chemosensory abilities and nasal
603 blockage. All participants had a diagnosis via a lab test. The thick black horizontal bar indicates
604 the median, the shaded bars within each violin indicates the interquartile range. The shaded
605 violin area in purple and blue represents smoothed histogram of data density along the data
606 points.

607
608
609 **Figure 3.** Self-reported change in smell (A), taste (B), chemesthesis (C), and nasal obstruction
610 (D) ratings in C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or without
611 obesity (OB-). Each panel presents the distribution of the change scores, i.e., the rating “before”
612 illness minus the rating “during” illness on the 100-point visual analog scale. All participants had
613 a diagnosis via a lab test. The thick black horizontal bar indicates the median, the shaded bars
614 within each violin indicates the interquartile range. The shaded violin area in purple and blue
615 represents smoothed histogram of data density along the data points.

616
617
618 **Figure 4.** Self-reported change in smell (A), taste (B), chemesthesis (C), and nasal obstruction
619 (D) ratings post-recovery from respiratory illness in C19+ (in purple) and C19- (in blue)
620 participants with obesity (OB+) or without obesity (OB-). Ratings were given on 0-100 visual
621 analog scales. Each panel presents the mean ratings for chemosensory abilities and nasal
622 blockage post-recovery from respiratory illness. All participants had a diagnosis via a lab
623 test. The thick black horizontal bar indicates the median, the shaded bars within each violin
624 indicates the interquartile range. The shaded violin area in purple and blue represents smoothed
625 histogram of data density along the data points.

626
627

628 **Figure 5.** Self-reported symptomatic manifestation reported by C19+ (in purple) and C19- (in
629 blue) participants with obesity (OB+) or without obesity (OB-). **(A)** Cumulative number of
630 symptoms reported by C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or
631 without obesity (OB-).
632 **(B)** Self-reported average number of days since onset of respiratory illness symptoms reported
633 by C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or without obesity (OB-).
634 **(C)** Proportion of participants with C19+ that report specific symptoms by self-reported obesity
635 (OB+) or without obesity (OB-). * $p < 0.05$. The thick black horizontal bar indicates the median,
636 the shaded bars within each violin indicates the interquartile range. The shaded violin area in
637 purple and blue represents smoothed histogram of data density along the data points.

638
639

640 **Figure 6.** ROC curve in discriminating C19+ vs. C19- in participants with obesity (OB+) after
641 having trained the model with participants without obesity (OB-).











